DRAK2 Polyclonal Antibody, PE Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-10467r-pe-100uL |
| Product Name | DRAK2 Polyclonal Antibody, PE Conjugated |
| Applications |
IF(ICC)
IF
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human DRAK2 |
| Immunogen Range | 281-372/372 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9262 |
| Swiss Prot | O94768 |
| Synonyms | DAP kinase related apoptosis inducing protein; DAP kinase related apoptosis inducing protein kinase 2; Death associated protein kinase related 2; DRAK 2; Serine/threonine kinase 17b (apoptosis inducing); Serine/threonine kinase 17b; Serine/threonine protein kinase 17B; STK17B; ST17B_HUMAN. |
| Background | Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. |
| Application Dilution | |
| IF(ICC) | 1:50-200 |
| IF | |
Frequently asked questions
Which applications is DRAK2 Polyclonal Antibody, PE Conjugated (bs-10467R-PE) validated for, and at what dilution?
bs-10467R-PE is validated for IF(ICC) (1:50-200); IF. These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does DRAK2 Polyclonal Antibody, PE Conjugated (bs-10467R-PE) react with?
Tested reactivity: Human, Mouse, Rat.
How should bs-10467R-PE be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise DRAK2 Polyclonal Antibody, PE Conjugated (bs-10467R-PE)?
KLH conjugated synthetic peptide derived from human DRAK2 Immunogen range: 281-372/372.
What are the excitation and emission wavelengths of the PE conjugate (bs-10467R-PE)?
PE on bs-10467R-PE: excitation / emission 496,564nm/578nm.